Siamab Therapeutics’ Antibody Drug Conjugates Show Promising Results in Ovarian Cancer

Siamab Therapeutics’ Antibody Drug Conjugates Show Promising Results in Ovarian Cancer
On Sept. 12, at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium in Seattle, Siamab Therapeutics declared that its new ST1 antibody drug conjugates (ADCs) have the ability to target chemotherapy-resistant ovarian cancer cells, showing strong efficacy in ovarian cancer models. “We have developed multiple anti-glycan antibodies and ADCs with unprecedented cancer

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *